SEARCH:   Advanced

Blood, 15 December 2003, Vol. 102, No. 13, pp. 4594-4599. Prepublished online as a Blood First Edition Paper on August 14, 2003; DOI 10.1182/blood-2002-11-3566. This Article Full Text Full Text (PDF) All Versions of this Article: 2002-11-3566v1 102/13/4594    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Reiter, R. A. Articles by Jilma, B. Search for Related Content PubMed PubMed Citation Articles by Reiter, R. A. Articles by Jilma, B. Related Collections Hemostasis, Thrombosis, and Vascular Biology Transfusion Medicine Cell Adhesion and Motility Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSFUSION MEDICINE Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin Rosemarie A. Reiter, Florian Mayr, Hannes Blazicek, Elisabeth Galehr, Petra Jilma-Stohlawetz, Hans Domanovits, and Bernd Jilma From the Departments of Clinical Pharmacology, Pharmacology, Blood Group Serology and Transfusion Medicine, and Emergency Medicine, University of Vienna, Austria. Whereas bleeding is the most frequent adverse event encountered in patients receiving glycoprotein (GP) IIb/IIIa inhibitors, there are currently no recommendations for how to treat such patients. The present study tested the hypothesis that infusion of desmopressin (DDAVP) reverses the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors (+L-aspirin). Study group 1 (10 healthy volunteers) received a DDAVP infusion to establish dose-response curves for the in vitro inhibition of platelet function by eptifibatide, abciximab, and tirofiban together with L-aspirin before and after DDAVP. In a randomized, double-blind, placebo-controlled, crossover study (group 2) volunteers received L-aspirin and a standard eptifibatide infusion. Thereafter, DDAVP or a physiologic saline infusion was given over 30 minutes. In group 1, all GPIIb/IIIa inhibitors prolonged collagen-epinephrine (CEPI) and collagen-adenosine diphosphate (CADP) closure times (CTs), measured with the platelet function analyzer 100 (PFA-100). DDAVP caused a shift in the concentration response curves to the right of all 3 GPIIb/IIIa inhibitors. In group 2, DDAVP accelerated the normalization of CADP-CT and CEPI-CT after the stop of eptifibatide infusion with a maximum effect at 1.5 hours to 2 hours. In contrast, CEPI-CT remained above normal in the placebo group for more than 4 hours. In conclusion, DDAVP accelerates normalization of the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors (+L-aspirin). (Blood. 2003;102:4594-4599) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. Homoncik, A. Gessl, A. Ferlitsch, B. Jilma, and H. Vierhapper Altered Platelet Plug Formation in Hyperthyroidism and Hypothyroidism J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3006 - 3012. [Abstract] [Full Text] [PDF] C. P. M. Hayward Diagnosis and Management of Mild Bleeding Disorders Hematology, January 1, 2005; 2005(1): 423 - 428. [Abstract] [Full Text] [PDF] M. Frossard, I. Fuchs, J. M. Leitner, K. Hsieh, M. Vlcek, H. Losert, H. Domanovits, W. Schreiber, A. N. Laggner, and B. Jilma Platelet Function Predicts Myocardial Damage in Patients With Acute Myocardial Infarction Circulation, September 14, 2004; 110(11): 1392 - 1397. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020